Humoral immune response to thymidylate synthase in colon cancer patients after 5-FU chemotherapy

  • Yuriy V. Shebzukhov
  • , Ekaterina P. Koroleva
  • , Svetlana V. Khlgatian
  • , Maria A. Lagarkova
  • , Andrey A. Meshcheryakov
  • , Mikhail R. Lichinitser
  • , Julia Karbach
  • , Elke Jager
  • , Dmitry V. Kuprash
  • , Sergei A. Nedospasov

Research output: Contribution to journalArticlepeer-review

11 Scopus citations

Abstract

Thymidylate synthase (TYMS), the critical enzyme for DNA synthesis and a target for chemotherapy, was recently characterized as an oncogene and a potential target for specific immunotherapy. Here we report TYMS-specific antibody response in a fraction of colon cancer patients. Humoral immune response to TYMS is induced by chemotherapy using TYMS inhibitors, such as 5-fluorouracil (5-FU), and may be associated with tumor burden. Therefore, TYMS may serve as a useful serological biomarker for monitoring the course of disease and treatment in cancer patients.

Original languageEnglish (US)
Pages (from-to)88-93
Number of pages6
JournalImmunology Letters
Volume100
Issue number1
DOIs
StatePublished - Aug 15 2005
Externally publishedYes

Keywords

  • 5-Fluorouracil (5-FU)
  • Antibodies
  • Serology
  • Thymidylate synthase (TYMS)

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Fingerprint

Dive into the research topics of 'Humoral immune response to thymidylate synthase in colon cancer patients after 5-FU chemotherapy'. Together they form a unique fingerprint.

Cite this